Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
STVN vs BCPC vs INGR vs APOG
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Packaged Foods
Construction
STVN vs BCPC vs INGR vs APOG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Chemicals - Specialty | Packaged Foods | Construction |
| Market Cap | $4.92B | $5.11B | $6.77B | $787M |
| Revenue (TTM) | $1.18B | $1.06B | $7.22B | $1.40B |
| Net Income (TTM) | $139M | $158M | $729M | $54M |
| Gross Margin | 29.0% | 36.3% | 25.3% | 22.7% |
| Operating Margin | 16.5% | 21.0% | 14.1% | 6.7% |
| Forward P/E | 29.3x | 30.9x | 9.6x | 10.6x |
| Total Debt | $471M | $192M | $1.79B | $286M |
| Cash & Equiv. | $131M | $75M | $1.03B | $40M |
STVN vs BCPC vs INGR vs APOG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Stevanato Group S.p… (STVN) | 100 | 89.3 | -10.7% |
| Balchem Corporation (BCPC) | 100 | 118.2 | +18.2% |
| Ingredion Incorpora… (INGR) | 100 | 122.3 | +22.3% |
| Apogee Enterprises,… (APOG) | 100 | 92.2 | -7.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STVN vs BCPC vs INGR vs APOG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
STVN lags the leaders in this set but could rank higher in a more targeted comparison.
BCPC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 8.8%, EPS growth 20.9%, 3Y rev CAGR 3.2%
- 160.5% 10Y total return vs INGR's 13.5%
- 8.8% revenue growth vs INGR's -2.8%
- 15.0% margin vs APOG's 3.9%
INGR is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 3 yrs, beta 0.25, yield 3.0%
- Lower volatility, beta 0.25, Low D/E 41.0%, current ratio 2.66x
- Beta 0.25, yield 3.0%, current ratio 2.66x
- Beta 0.25 vs STVN's 1.45
APOG is the clearest fit if your priority is valuation efficiency.
- PEG 0.32 vs STVN's 2.48
- Lower P/E (10.6x vs 30.9x), PEG 0.32 vs 2.41
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.8% revenue growth vs INGR's -2.8% | |
| Value | Lower P/E (10.6x vs 30.9x), PEG 0.32 vs 2.41 | |
| Quality / Margins | 15.0% margin vs APOG's 3.9% | |
| Stability / Safety | Beta 0.25 vs STVN's 1.45 | |
| Dividends | 3.0% yield, 3-year raise streak, vs APOG's 2.8% | |
| Momentum (1Y) | -2.2% vs INGR's -18.4% | |
| Efficiency (ROA) | 9.4% ROA vs APOG's 4.8%, ROIC 15.5% vs 8.1% |
STVN vs BCPC vs INGR vs APOG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
STVN vs BCPC vs INGR vs APOG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BCPC leads in 2 of 6 categories
APOG leads 1 • INGR leads 1 • STVN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BCPC leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INGR is the larger business by revenue, generating $7.2B annually — 6.8x BCPC's $1.1B. BCPC is the more profitable business, keeping 15.0% of every revenue dollar as net income compared to APOG's 3.9%. On growth, BCPC holds the edge at +8.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $1.1B | $7.2B | $1.4B |
| EBITDAEarnings before interest/tax | $283M | $267M | $1.2B | $57M |
| Net IncomeAfter-tax profit | $139M | $158M | $729M | $54M |
| Free Cash FlowCash after capex | $16M | $182M | $809M | $95M |
| Gross MarginGross profit ÷ Revenue | +29.0% | +36.3% | +25.3% | +22.7% |
| Operating MarginEBIT ÷ Revenue | +16.5% | +21.0% | +14.1% | +6.7% |
| Net MarginNet income ÷ Revenue | +11.8% | +15.0% | +10.1% | +3.9% |
| FCF MarginFCF ÷ Revenue | +1.4% | +17.2% | +11.2% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.8% | +8.1% | -2.4% | +1.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -5.6% | +10.6% | +79.0% | +6.1% |
Valuation Metrics
APOG leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 9.6x trailing earnings, INGR trades at a 71% valuation discount to BCPC's 33.6x P/E. Adjusting for growth (PEG ratio), APOG offers better value at 0.43x vs STVN's 2.64x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $4.9B | $5.1B | $6.8B | $787M |
| Enterprise ValueMkt cap + debt − cash | $5.3B | $5.2B | $7.5B | $1.0B |
| Trailing P/EPrice ÷ TTM EPS | 31.31x | 33.58x | 9.61x | 14.52x |
| Forward P/EPrice ÷ next-FY EPS est. | 29.32x | 30.87x | 9.56x | 10.64x |
| PEG RatioP/E ÷ EPS growth rate | 2.64x | 2.62x | 0.57x | 0.43x |
| EV / EBITDAEnterprise value multiple | 16.89x | 19.83x | 5.98x | 21.95x |
| Price / SalesMarket cap ÷ Revenue | 3.68x | 4.92x | 0.94x | 0.56x |
| Price / BookPrice ÷ Book value/share | 2.82x | 4.14x | 1.60x | 1.53x |
| Price / FCFMarket cap ÷ FCF | 195.36x | 29.51x | 13.25x | 8.27x |
Profitability & Efficiency
INGR leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INGR delivers a 17.1% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $10 for STVN. BCPC carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to APOG's 0.56x. On the Piotroski fundamental quality scale (0–9), BCPC scores 9/9 vs STVN's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.7% | +12.4% | +17.1% | +10.8% |
| ROA (TTM)Return on assets | +5.8% | +9.4% | +9.4% | +4.8% |
| ROICReturn on invested capital | +7.7% | +12.2% | +15.5% | +8.1% |
| ROCEReturn on capital employed | +9.5% | +14.8% | +16.3% | +9.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 9 | 8 | 7 |
| Debt / EquityFinancial leverage | 0.32x | 0.15x | 0.41x | 0.56x |
| Net DebtTotal debt minus cash | $340M | $117M | $760M | $247M |
| Cash & Equiv.Liquid assets | $131M | $75M | $1.0B | $40M |
| Total DebtShort + long-term debt | $471M | $192M | $1.8B | $286M |
| Interest CoverageEBIT ÷ Interest expense | 20.54x | 15.23x | 27.32x | 5.97x |
Total Returns (Dividends Reinvested)
BCPC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INGR five years ago would be worth $12,881 today (with dividends reinvested), compared to $9,282 for STVN. Over the past 12 months, BCPC leads with a -2.2% total return vs INGR's -18.4%. The 3-year compound annual growth rate (CAGR) favors BCPC at 8.2% vs STVN's -13.8% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -12.4% | +3.6% | -0.7% | -1.3% |
| 1-Year ReturnPast 12 months | -17.0% | -2.2% | -18.4% | -2.8% |
| 3-Year ReturnCumulative with dividends | -35.9% | +26.6% | +7.9% | -0.1% |
| 5-Year ReturnCumulative with dividends | -7.2% | +24.2% | +28.8% | +12.9% |
| 10-Year ReturnCumulative with dividends | -7.2% | +160.5% | +13.5% | +10.5% |
| CAGR (3Y)Annualised 3-year return | -13.8% | +8.2% | +2.6% | -0.0% |
Risk & Volatility
Evenly matched — BCPC and INGR each lead in 1 of 2 comparable metrics.
Risk & Volatility
INGR is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than STVN's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BCPC currently trades 86.7% from its 52-week high vs STVN's 64.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 0.33x | 0.25x | 1.25x |
| 52-Week HighHighest price in past year | $28.00 | $183.90 | $141.78 | $49.99 |
| 52-Week LowLowest price in past year | $12.89 | $139.17 | $100.71 | $30.75 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +86.7% | +75.8% | +73.2% |
| RSI (14)Momentum oscillator 0–100 | 82.1 | 32.9 | 27.3 | 53.6 |
| Avg Volume (50D)Average daily shares traded | 583K | 190K | 585K | 253K |
Analyst Outlook
Evenly matched — INGR and APOG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: STVN as "Buy", BCPC as "Buy", INGR as "Hold", APOG as "Hold". Consensus price targets imply 92.7% upside for APOG (target: $71) vs 1.6% for BCPC (target: $162). For income investors, INGR offers the higher dividend yield at 3.01% vs STVN's 0.34%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $24.50 | $162.00 | $124.25 | $70.50 |
| # AnalystsCovering analysts | 8 | 10 | 21 | 6 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | +0.5% | +3.0% | +2.8% |
| Dividend StreakConsecutive years of raises | 0 | 11 | 3 | 14 |
| Dividend / ShareAnnual DPS | $0.05 | $0.87 | $3.24 | $1.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.1% | +3.3% | +1.9% |
BCPC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). APOG leads in 1 (Valuation Metrics). 2 tied.
STVN vs BCPC vs INGR vs APOG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is STVN or BCPC or INGR or APOG a better buy right now?
For growth investors, Balchem Corporation (BCPC) is the stronger pick with 8.
8% revenue growth year-over-year, versus -2. 8% for Ingredion Incorporated (INGR). Ingredion Incorporated (INGR) offers the better valuation at 9. 6x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — STVN or BCPC or INGR or APOG?
On trailing P/E, Ingredion Incorporated (INGR) is the cheapest at 9.
6x versus Balchem Corporation at 33. 6x. On forward P/E, Ingredion Incorporated is actually cheaper at 9. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Apogee Enterprises, Inc. wins at 0. 32x versus Stevanato Group S. p. A. 's 2. 48x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — STVN or BCPC or INGR or APOG?
Over the past 5 years, Ingredion Incorporated (INGR) delivered a total return of +28.
8%, compared to -7. 2% for Stevanato Group S. p. A. (STVN). Over 10 years, the gap is even starker: BCPC returned +160. 5% versus STVN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — STVN or BCPC or INGR or APOG?
By beta (market sensitivity over 5 years), Ingredion Incorporated (INGR) is the lower-risk stock at 0.
25β versus Stevanato Group S. p. A. 's 1. 45β — meaning STVN is approximately 478% more volatile than INGR relative to the S&P 500. On balance sheet safety, Balchem Corporation (BCPC) carries a lower debt/equity ratio of 15% versus 56% for Apogee Enterprises, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — STVN or BCPC or INGR or APOG?
By revenue growth (latest reported year), Balchem Corporation (BCPC) is pulling ahead at 8.
8% versus -2. 8% for Ingredion Incorporated (INGR). On earnings-per-share growth, the picture is similar: Balchem Corporation grew EPS 20. 9% year-over-year, compared to -35. 2% for Apogee Enterprises, Inc.. Over a 3-year CAGR, STVN leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — STVN or BCPC or INGR or APOG?
Balchem Corporation (BCPC) is the more profitable company, earning 14.
9% net margin versus 3. 9% for Apogee Enterprises, Inc. — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCPC leads at 21. 1% versus 6. 0% for APOG. At the gross margin level — before operating expenses — BCPC leads at 35. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is STVN or BCPC or INGR or APOG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Apogee Enterprises, Inc. (APOG) is the more undervalued stock at a PEG of 0. 32x versus Stevanato Group S. p. A. 's 2. 48x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Ingredion Incorporated (INGR) trades at 9. 6x forward P/E versus 30. 9x for Balchem Corporation — 21. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for APOG: 92. 7% to $70. 50.
08Which pays a better dividend — STVN or BCPC or INGR or APOG?
All stocks in this comparison pay dividends.
Ingredion Incorporated (INGR) offers the highest yield at 3. 0%, versus 0. 3% for Stevanato Group S. p. A. (STVN).
09Is STVN or BCPC or INGR or APOG better for a retirement portfolio?
For long-horizon retirement investors, Balchem Corporation (BCPC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
33), 0. 5% yield, +160. 5% 10Y return). Both have compounded well over 10 years (BCPC: +160. 5%, STVN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between STVN and BCPC and INGR and APOG?
These companies operate in different sectors (STVN (Healthcare) and BCPC (Basic Materials) and INGR (Consumer Defensive) and APOG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: STVN is a small-cap quality compounder stock; BCPC is a small-cap quality compounder stock; INGR is a small-cap deep-value stock; APOG is a small-cap deep-value stock. BCPC, INGR, APOG pay a dividend while STVN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.